Please login to the form below

Not currently logged in

Pierre Fabre’s Braftovi gets EU okay for BRAF+ colorectal cancer

Drug is first to be specifically approved for this type of cancer in the EU

EMA logo

The EMA has approved Pierre Fabre’s Braftovi for the treatment BRAF-positive colorectal cancer, making it the first drug specifically approved for this type of cancer in the EU.

BRAF inhibitor Braftovi (encorafenib) has been cleared in a regimen alongside Merck KGaA’s EGFR-targeting antibody Erbitux (cetuximab) for second-line treatment of BRAF+ colorectal cancer patients previously treated with other systemic therapies.

Braftovi was approved for the same indication in April in the US, where it is sold by Pfizer – and was one of the key elements in the big pharma company’s $11.4bn takeover of Array Biopharma last year, particularly for its potential as a colorectal cancer treatment.

Braftovi is already approved to treat BRAF+ melanoma – a form of skin cancer – as a combination therapy with MEK inhibitor Mektovi (binimetinib), and analysts at EvaluatePharma think that colorectal cancer will account for more than $700m of the drug’s predicted global sales in 2024 of $1.2bn. Pfizer claimed approval for the colorectal cancer indication from the FDA in April.

The latest EU approval – which also covers the UK, Norway, Iceland and Liechtenstein – follows the BEACON CRC trial, which according to Pierre Fabre is the first and only phase 3 study to test a BRAF combination targeted therapy in BRAF+ colorectal cancer.

The results showed that Braftovi/Erbitux significantly improved overall survival (OS) by 40% compared to Erbitux and irinotecan-based chemotherapy, with a median OS of 9.3 months and 5.9 months, respectively.

Data from the trial also showed that the two-drug combination was as effective as a triple therapy which also included Mektovi, which meant that additional toxicity from the MEK inhibitor could be avoided without compromising patient benefits.

The trial has established Braftovi and Erbitux as a standard therapy for second-line BRAF-mutant colorectal cancer, but trials are already underway that will try to move the combination into the front-line setting.

The phase 2 ANCHOR CRC trial, which started in 2018 before the BEACON CRC results were mature, is testing triple therapy with Braftovi/Mektovi plus Erbitux or another EGFR inhibitor – Amgen’s Vectibix (panitumumab) – as a chemotherapy-free option for patients. It is due to generate results this month.

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths, with about 1.8m new  diagnoses globally, and of these 7-10% have BRAF mutations.

Novartis is also testing its BRAF/MEK combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive colorectal cancer, and recently started trials of the duo alongside other Novartis drugs, including its experimental PD-1 inhibitor PDR001, in this indication.

Article by
Phil Taylor

4th June 2020

From: Research, Regulatory, Healthcare



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...